Literature DB >> 24170196

Concordance of resistance profiles in households of patients with multidrug-resistant tuberculosis.

Jonathan B Parr1, Carole D Mitnick, Sidney S Atwood, Katiuska Chalco, Jaime Bayona, Mercedes C Becerra.   

Abstract

We estimated the proportion of household contacts whose drug-susceptibility test results matched those of the purported source patient with multidrug-resistant tuberculosis. Ninety-nine (88.4%) contacts had isolates resistant to isoniazid and rifampin, and 41 (36.6%) contacts had isolates with results that also matched the purported source for ethambutol, streptomycin, and pyrazinamide.

Entities:  

Keywords:  DST; contact; discordant; empirical; presumptive

Mesh：

Substances：

Year:  2013        PMID： 24170196      PMCID： PMC3890336          DOI： 10.1093/cid/cit709

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  Effect of administering short-course, standardized regimens in individuals infected with drug-resistant Mycobacterium tuberculosis strains.

Authors:  J J Furin; M C Becerra; S S Shin; J Y Kim; J Bayona; P E Farmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-02       Impact factor: 3.267

Review 2.  Management of children exposed to multidrug-resistant Mycobacterium tuberculosis.

Authors:  James A Seddon; Peter Godfrey-Faussett; Anneke C Hesseling; Robert P Gie; Nulda Beyers; H Simon Schaaf
Journal:  Lancet Infect Dis       Date:  2012-02-27       Impact factor: 25.071

3.  Discordant drug susceptibility for mycobacterium tuberculosis within families.

Authors:  James A Seddon; Annemie M Jordaan; Thomas C Victor; H Simon Schaaf
Journal:  Pediatr Infect Dis J       Date:  2012-07       Impact factor: 2.129

4.  Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-06-09

5.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.

Authors:  Molly F Franke; Sasha C Appleton; Carole D Mitnick; Jennifer J Furin; Jaime Bayona; Katiuska Chalco; Sonya Shin; Megan Murray; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

6.  Contact investigations as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis.

Authors:  J Bayona; A M Chavez-Pachas; E Palacios; K Llaro; R Sapag; M C Becerra
Journal:  Int J Tuberc Lung Dis       Date:  2003-12       Impact factor: 2.373

7.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

Review 8.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani
Journal:  Lancet Infect Dis       Date:  2009-03       Impact factor: 25.071

9.  Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru.

Authors:  Ted Cohen; Megan Murray; Ibrahim Abubakar; Zibiao Zhang; Alexander Sloutsky; Fernando Arteaga; Katiuska Chalco; Molly F Franke; Mercedes C Becerra
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

10.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240
View more
  5 in total

1.  Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.

Authors:  H Simon Schaaf
Journal:  Indian J Pediatr       Date:  2019-01-17       Impact factor: 1.967

2.  The 4-aminopiperidine series has limited anti-tubercular and anti-staphylococcus aureus activity.

Authors:  N Susantha Chandrasekera; Torey Alling; Mai Bailey; Aaron Korkegian; James Ahn; Yulia Ovechkina; Joshua Odingo; Tanya Parish
Journal:  J Negat Results Biomed       Date:  2015-02-13

Review 3.  Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Authors:  Aparna Mukherjee; Rakesh Lodha; Sushil Kumar Kabra
Journal:  Expert Opin Pharmacother       Date:  2017-10-09       Impact factor: 3.889

4.  Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).

Authors:  James A Seddon; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Anne-Marie Demers; Graeme Hoddinott; Angela M Crook; Ellen Owen-Powell; Margaret J Thomason; Anna Turkova; Diana M Gibb; Lee Fairlie; Neil Martinson; H Simon Schaaf; Anneke C Hesseling
Journal:  Trials       Date:  2018-12-20       Impact factor: 2.279

5.  Analysis of Factors Influencing Multidrug-Resistant Tuberculosis and Validation of Whole-Genome Sequencing in Children with Drug-Resistant Tuberculosis.

Authors:  Ying Zhang; Ruiqiu Zhao; Zhenzhen Zhang; Quanbo Liu; Aihua Zhang; Qiaoli Ren; Siyuan Li; Xiaoru Long; Hongmei Xu
Journal:  Infect Drug Resist       Date:  2021-10-24       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.